posted 07-03-2000 10:57 AM         

What would you buy today if you could pick just one stock for your retirement portfolio? Money Magazine asked this question to several dozen prominent investors, from high-flying hedge fund and mutual fund managers to top Wall Street strategists and analysts. http://www.money.com/money/magazine/longterm/

posted 06-29-2000 06:30 PM         

Legg Mason analyst Randy Befumo presents the case for Amazon.com in a three-part series (source: TheStreet.com):
Part 1 looks at 5 key issues facing Amazon: http://www.thestreet.com/comment/herbonthestreet/979871.html
Part 2 rebuts the claim that Amazon is running out of money: http://www.thestreet.com/comment/herbonthestreet/979915.html
Part 3 makes a case for Amazon as a great investment: http://www.thestreet.com/comment/herbonthestreet/979956.html

In brief:

- Companies that sell goods and services over the Internet are responsible for almost 5,400 lost jobs since December 1999, according to a report from Chicago, Illinois-based employment company Challenger, Gray & Christmas.
- Internet keyword company RealNames laid off about 20% of its work force this week, succumbing to the growing financial reality-check gripping the Internet industry.

posted 06-26-2000 01:37 PM           

ATI was incorporated under the laws of the State of Delaware in December 1998. The Company is a “start-up” venture, with no operating history, which intends to seek investment and acquisition opportunities in the e-commerce, internet and telecommunications industries. Specifically, ATI believes that strategic opportunities exist to acquire and consolidate small 4th & 5th tier telecommunications companies and provide these companies with broadband service. The Company believes that as the growing reliance on the internet becomes widespread, building a new reliable high-performance backbone and supplying the bandwidth for greater applications will become a priority. Current forms of broadband service such as DSL (Digital Subscriber Lines) are not expected to satisfy the broadband problem.
The Company believes that rural America and certain suburban areas have been overlooked in the expansion of the telecommunications industry and that, as a result, micro-niche markets may exist in rural/suburban areas with populations from 200,000 to 500,000 that do not currently have access to broadband service. ATI’s objective is to identify small, existing 4th & 5th tier telecommunication companies in these micro-niche areas, to acquire such companies and combine them into stronger, regional entities and to provide such companies and their customers with microwave and/or optical laser photon technology. The Company believes that by using the fiber optic backbone that exists today to reach suburban neighborhoods, microwave and or laser signals can bypass traditional copper telephone lines offering broadband service.

posted 06-16-2000 06:19 PM         

Upside's Richard Brandt looks back on his Y2K predictions. (source: Upside) http://www.upside.com/Richard_Brandt/

Market strategist Charles Payne of Wall Street Strategies says he sees investors making lots of mistakes in this market. Here, he tells how he draws on a mix of technicals, fundamentals, market timing and instinct to make good picks. (source: MoneyCentral) http://moneycentral.msn.com/articles/invest/inter/5481.asp

posted 06-16-2000 03:21 PM         

FRCD...GREAT COMPANY TO CHECK INTO!!!

COMPANY OVERVIEW
Fairchild International Corporation (NQB-Pink: FRCD)

Website: http://www.fairchildinternational.com

SEC Filing Status: Waiting on SEC Approval

Share Structure:
Outstanding: 11 Million
Float: 500,000
Options: None
Warrants: None

HEAD OFFICE:

President: Byron Cox
600-595 Hornby Street
Vancouver, B.C. V6C 1A4 Canada
Phone: 1 604 646 5614
Fax: 1 604 646 5649
E-mail: invest@istar.ca

IN THE U.S.A.
3600-701 fifth Avenue
Seattle, Washington 98104 USA
Toll Free: 1 800 249 7996

INVESTOR INFORMATION

Industry: Healthcare
Research Into Non-Prescription Medical Treatments
Fairchild International Corporation is a publicly-traded U.S. Corporation. It has a pharmaceutical research division for the development of non-prescription medical treatments and an alternative medicine Internet portal under development for specialized healthcare information and products.

Fairchild International's goal is to become a leader in the development of alternative health information and proprietary health care products for consumers. A primary focus will be the close to 100 million North Americans between 34 and 50 who are considered to be the affluent Baby-Boomer generation. At the same time Fairchild International is developing its Internet portal www.healthypharmacy.com to offer the latest information on alternative medicine developments as well as specialized healthcare products.

HealthyPharmacy.com will join other "nutraceutical" Internet companies such as Drugstore.com, MotherNature.com and Vitamins.com in providing natural health services and products over the internet.

RESEARCH

Fairchild has a partnership with Praxis Pharmaceuticals Inc. www.praxis-pharmaceuticals.com ,a world leader in the field of therapeutic carbohydrate based science. for the development of two revolutionary over-the-counter proprietary products. One product is for deep facial wrinkles and the other is for rheumatoid arthritis. According to various independent market surveys, the potential market for the anti-wrinkle product is valued at over $4-billion, while the arthritis treatment is estimated at $4-billion.

A Fountain of Youth?

The skin regeneration anti-wrinkle product treats deep facial wrinkles through topical application (applied to the skin surface). If research continues showing highly successful results, Fairchild could be the first company in the field of dermatology to create a clinically-proven topical treatment for deep wrinkles. Among the current treatments for deep wrinkles are expensive needle injections using collagen from cows, which can cause a reaction in humans as well as painful and expensive facial surgery.

Since the Fairchild product is a natural formulation applied to the skin surface, it could be the next major discovery in the skin care industry as alpha hydroxy acids were a few years ago in treating surface wrinkles.
Fairchild has been approached by a major pharmaceutical company regarding the acquisition of the anti-deep wrinkle formula, but company officials say no decision will be made in this regard until the patent process is completed (End of June)and the product ready for market.

A Safe and Effective Treatment for Arthritis?

The arthritis product is also a natural formula and has been shown in animal studies to be an effective and safe treatment for this debilitating disease. Millions of people suffer from rheumatoid arthritis. Currently, there are no safe and effective treatments. All the drugs on the market today, including NSAIDs, corticosteroids, antimetabolites, cyclosporin and other drugs have negative reactions, some of which could be life-threatening. Healthcare costs relating to rheumatoid arthritis are estimated to be around $5 billion annually in the United States.

Introduction of both products to these markets is expected to be within the next twelve months as patents are finalized and product research is completed. Because the anti-wrinkle and arthritis therapies are natural-based formulas and can be sold over-the-counter, they do not require FDA approval.

Blue-Ribbon Research Team

The research and development team is head by Dr. William Cowden and Dr. Brett Charlton, who are the principal scientific advisors to Fairchild International.
Dr. Cowden is currently Senior Research Fellow at the world-renowned John Curtin School of Medical Research and Scientific Director for Praxis Pharmaceuticals. Dr. Cowden was previously Senior Scientist at Peptide Technology Ltd. As part of his work with the commercial sector, Dr. Cowden has been involved in drug development studies from the earliest states of identification of drug candidates, including pre-clinical assessment, up to the early clinical trial stages. Agents discovered in his laboratory are currently licensed by major pharmaceutical companies. He has published over 100 papers in peer-reviewed scientific and medical journals, and is inventor or co-inventor on seven pharmaceutical patents. Dr. Cowden is based in Canberra, Australia.

Dr. Charlton has extensive experience in technology assessment and clinical trial management. He has held academic appointments at the Walter and Eliza Hall Institute and Stanford University and is also at the John Curtin School of Medical Research. Dr. Charlton is also the clinical coordinator of the Clinical Studies Section of the National Health Sciences Center. He spent three years with Baxter Healthcare as a research manager, where he was involved in new technology assessment, strategic planning and clinical trial management. He has been consulting for the biomedical and pharmaceutical industry since 1984 and has published more than 50 scientific papers in medical and biomedical journals. Dr. Charlton also serves as Medical Director for Praxis. He, too, is based in Canberra.

From a financial perspective, Praxis has attracted the attention of a number of international financial organizations, including the Rothschild group which recently announced an investment in the company relating to its prescription drug formulations. Praxis products, including those now owned by Fairchild, have already seen some $7-million invested since research and development commenced.

THE INTERNET CONNECTION

Fairchild is positioning itself to supply the latest alternative medicine information and specialized healthcare products to Baby Boomers and others through the development of its web portal: (www.HealthyPharmacy.com)
In particular, the multi-billion dollar skin care industry is one of the largest global markets out there today.

Whether you want to recoup that younger look, enhancing what you have, skin care is at the top of the list of requests that people make to better or maintain their self-image. In this connection, Fairchild International offers the "fountain of youth" most Baby Boomers have been searching for.

Its product line is unsurpassed in quality and effectiveness. All formulas were developed in an FDA-inspected laboratory in compliance with rigid manufacturing guidelines. There is no question that its dermatologically-tested and hypoallergenic skin care system inhibits damage to cells that cause wrinkling and aging of the skin.

The company anticipates it will begin marketing its products via the Internet and through other media channels by the first quarter of next year. It will also offer other selected natural health care products from other companies that complement those produced by Fairchild.
Juniper Communications, an Internet research firm, estimates online shopping will increase fourfold from $12-billion this year to $48-billion in 2002.

HIGHLIGHTS

*Partnership with world medical leader in carbohydrate science.
*Market opportunity close to $10 billion.
*Proprietary products never before offered.
*Internet portal site under development to offer up-to- date alternative health information.
*Millions already invested in research and development
*Potential for increase in shareholder value.

posted 06-15-2000 09:06 AM         

quote:

---

Originally posted by InvestorGuide Daily:
Semiconductor stocks should surge over the coming months even if the economy slows down. Add Atmel to the list of chip makers Jim Jubak finds worth munching. (source: MoneyCentral) http://moneycentral.msn.com/articles/invest/jubak/5473.asp

---